Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Corneal Epithelial Stem Cells and Dry Eye Disease

NCT03302273 · View on ClinicalTrials.gov ↗

Study Summary

To study of a novel, therapeutic Human Cells, Tissues, and Cellular and Tissue-Based Product (HCT/P) in the treatment of severe dry eye disease that is failing conventional treatments. This pilot study will carefully observe and monitor each qualifying and willing individual for response to treatment, signs of toxicity and adverse effects from the treatment, and for ability of the treatment to improve comfort and restore vision.

Interventions

  • OTHER Corneal Epithelial Stem Cell Transplant

Study Locations (1)

Texas

  • Rush Eye Associates — Amarillo

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2019-02-01
Est. Completion 2022-04-01
Phase NA

Sponsor

Sloan W. Rush, MD

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03302273

The ClinicalTrials.gov registry entry for NCT03302273 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sloan W. Rush, MD, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 6 conditions, with Dry Eye appearing as the primary indexed condition, and to 1 intervention — of which Corneal Epithelial Stem Cell Transplant is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03302273 reports 1 study location spanning 1 distinct geographic area — top geographies include Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03302273 about?

NCT03302273 is a clinical study titled "Corneal Epithelial Stem Cells and Dry Eye Disease". To study of a novel, therapeutic Human Cells, Tissues, and Cellular and Tissue-Based Product (HCT/P) in the treatment of severe dry eye disease that is failing conventional treatments. This pilot study will carefully observe and monitor each qualifying and willing individual for response to treatmen...

What is the current status of trial NCT03302273?

This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2019-02-01. Estimated completion is 2022-04-01.

What conditions does trial NCT03302273 study?

This clinical trial studies the following conditions: Dry Eye, Dry Eye Syndromes, Blepharitis, Ocular Inflammation, Ocular Surface Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03302273?

The interventions under investigation include: Corneal Epithelial Stem Cell Transplant (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03302273?

This trial is sponsored by Sloan W. Rush, MD, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03302273 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial